BridgeBio Pharma Comprehensive Income 2018-2024 | BBIO
BridgeBio Pharma comprehensive income from 2018 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
- BridgeBio Pharma comprehensive income for the quarter ending June 30, 2024 was $0.000B, a 106.35% decline year-over-year.
- BridgeBio Pharma comprehensive income for 2023 was $0B, a 109.45% decline from 2022.
- BridgeBio Pharma comprehensive income for 2022 was $-0B, a 148.48% increase from 2021.
- BridgeBio Pharma comprehensive income for 2021 was $-0B, a 168.75% decline from 2020.
BridgeBio Pharma Annual Comprehensive Income
(Millions of US $) |
| 2023 |
$0 |
| 2022 |
$-0 |
| 2021 |
$-0 |
| 2020 |
$0 |
| 2019 |
$0 |
| 2018 |
$ |
| 2017 |
$ |
BridgeBio Pharma Quarterly Comprehensive Income
(Millions of US $) |
| 2024-06-30 |
$-0 |
| 2024-03-31 |
$0 |
| 2023-12-31 |
$0 |
| 2023-09-30 |
$0 |
| 2023-06-30 |
$0 |
| 2023-03-31 |
$-0 |
| 2022-12-31 |
$-0 |
| 2022-09-30 |
$-0 |
| 2022-06-30 |
$-0 |
| 2022-03-31 |
$-0 |
| 2021-12-31 |
$-0 |
| 2021-09-30 |
$0 |
| 2021-06-30 |
$0 |
| 2021-03-31 |
$-0 |
| 2020-12-31 |
$0 |
| 2020-09-30 |
$0 |
| 2020-06-30 |
$1 |
| 2020-03-31 |
$1 |
| 2019-12-31 |
$0 |
| 2019-09-30 |
$0 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$5.028B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
